Penile carcinoma

the case for primary lymphadenectomy.

Michael Koch, W. S. McDougal

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

In the preceding sections, the authors have presented an approach to the management of patients with squamous-cell carcinoma of the penis selected to maximize the therapeutic benefits in high-risk patients while minimizing morbidity in low-risk patients. A clinical staging system is presented in order to approach this problem in a logical fashion. Patients with stage I penile carcinomas are all managed by eradication of the primary lesion followed by expectant management of the inguinal lymph nodes. Persistent inguinal adenopathy after treatment of the primary lesion has been a very rare occurrence in this group of patients in our experience. Patients with stage II penile carcinoma are managed by eradication of the primary lesion, 6-8 weeks of antibiotic therapy, and inguinal lymphadenectomy. The available literature suggests a high incidence of inguinal lymphatic metastases in this group of patients and supports the need for early lymphadenectomy. Finally, patients with clinical stage III disease, i.e., persistent adenopathy after eradication of the primary lesion and 6-8 weeks of antibiotic therapy, all undergo inguinal lymphadenectomy. This group is at extremely high risk and does poorly without aggressive surgical management.

Original languageEnglish
Pages (from-to)55-64
Number of pages10
JournalCancer Treatment and Research
Volume46
StatePublished - 1989
Externally publishedYes

Fingerprint

Lymph Node Excision
Groin
Carcinoma
Anti-Bacterial Agents
Lymphatic Metastasis
Penis
Therapeutics
Squamous Cell Carcinoma
Lymph Nodes
Morbidity
Incidence

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Penile carcinoma : the case for primary lymphadenectomy. / Koch, Michael; McDougal, W. S.

In: Cancer Treatment and Research, Vol. 46, 1989, p. 55-64.

Research output: Contribution to journalArticle

@article{4daa6cf45d124dbe86964e762227d21d,
title = "Penile carcinoma: the case for primary lymphadenectomy.",
abstract = "In the preceding sections, the authors have presented an approach to the management of patients with squamous-cell carcinoma of the penis selected to maximize the therapeutic benefits in high-risk patients while minimizing morbidity in low-risk patients. A clinical staging system is presented in order to approach this problem in a logical fashion. Patients with stage I penile carcinomas are all managed by eradication of the primary lesion followed by expectant management of the inguinal lymph nodes. Persistent inguinal adenopathy after treatment of the primary lesion has been a very rare occurrence in this group of patients in our experience. Patients with stage II penile carcinoma are managed by eradication of the primary lesion, 6-8 weeks of antibiotic therapy, and inguinal lymphadenectomy. The available literature suggests a high incidence of inguinal lymphatic metastases in this group of patients and supports the need for early lymphadenectomy. Finally, patients with clinical stage III disease, i.e., persistent adenopathy after eradication of the primary lesion and 6-8 weeks of antibiotic therapy, all undergo inguinal lymphadenectomy. This group is at extremely high risk and does poorly without aggressive surgical management.",
author = "Michael Koch and McDougal, {W. S.}",
year = "1989",
language = "English",
volume = "46",
pages = "55--64",
journal = "Cancer Treatment and Research",
issn = "0927-3042",
publisher = "Springer Netherlands",

}

TY - JOUR

T1 - Penile carcinoma

T2 - the case for primary lymphadenectomy.

AU - Koch, Michael

AU - McDougal, W. S.

PY - 1989

Y1 - 1989

N2 - In the preceding sections, the authors have presented an approach to the management of patients with squamous-cell carcinoma of the penis selected to maximize the therapeutic benefits in high-risk patients while minimizing morbidity in low-risk patients. A clinical staging system is presented in order to approach this problem in a logical fashion. Patients with stage I penile carcinomas are all managed by eradication of the primary lesion followed by expectant management of the inguinal lymph nodes. Persistent inguinal adenopathy after treatment of the primary lesion has been a very rare occurrence in this group of patients in our experience. Patients with stage II penile carcinoma are managed by eradication of the primary lesion, 6-8 weeks of antibiotic therapy, and inguinal lymphadenectomy. The available literature suggests a high incidence of inguinal lymphatic metastases in this group of patients and supports the need for early lymphadenectomy. Finally, patients with clinical stage III disease, i.e., persistent adenopathy after eradication of the primary lesion and 6-8 weeks of antibiotic therapy, all undergo inguinal lymphadenectomy. This group is at extremely high risk and does poorly without aggressive surgical management.

AB - In the preceding sections, the authors have presented an approach to the management of patients with squamous-cell carcinoma of the penis selected to maximize the therapeutic benefits in high-risk patients while minimizing morbidity in low-risk patients. A clinical staging system is presented in order to approach this problem in a logical fashion. Patients with stage I penile carcinomas are all managed by eradication of the primary lesion followed by expectant management of the inguinal lymph nodes. Persistent inguinal adenopathy after treatment of the primary lesion has been a very rare occurrence in this group of patients in our experience. Patients with stage II penile carcinoma are managed by eradication of the primary lesion, 6-8 weeks of antibiotic therapy, and inguinal lymphadenectomy. The available literature suggests a high incidence of inguinal lymphatic metastases in this group of patients and supports the need for early lymphadenectomy. Finally, patients with clinical stage III disease, i.e., persistent adenopathy after eradication of the primary lesion and 6-8 weeks of antibiotic therapy, all undergo inguinal lymphadenectomy. This group is at extremely high risk and does poorly without aggressive surgical management.

UR - http://www.scopus.com/inward/record.url?scp=0024810352&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024810352&partnerID=8YFLogxK

M3 - Article

VL - 46

SP - 55

EP - 64

JO - Cancer Treatment and Research

JF - Cancer Treatment and Research

SN - 0927-3042

ER -